DB:HTD

Stock Analysis Report

Executive Summary

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.


Snowflake Analysis

Flawless balance sheet and good value.


Similar Companies

Share Price & News

How has Corcept Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HTD has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.3%

HTD

-1.8%

DE Pharmaceuticals

-0.2%

DE Market


1 Year Return

26.4%

HTD

16.8%

DE Pharmaceuticals

13.7%

DE Market

Return vs Industry: HTD exceeded the German Pharmaceuticals industry which returned 17.6% over the past year.

Return vs Market: HTD exceeded the German Market which returned 14.4% over the past year.


Shareholder returns

HTDIndustryMarket
7 Day3.3%-1.8%-0.2%
30 Day10.4%1.1%0.3%
90 Day8.5%10.9%3.7%
1 Year26.4%26.4%20.8%16.8%17.2%13.7%
3 Year60.5%60.5%40.4%24.5%15.4%5.3%
5 Year324.0%324.0%38.0%14.4%21.3%4.7%

Price Volatility Vs. Market

How volatile is Corcept Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Corcept Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HTD (€12.7) is trading below our estimate of fair value (€30.29)

Significantly Below Fair Value: HTD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HTD is good value based on its PE Ratio (18.3x) compared to the Pharmaceuticals industry average (25.9x).

PE vs Market: HTD is good value based on its PE Ratio (18.3x) compared to the German market (20.7x).


Price to Earnings Growth Ratio

PEG Ratio: HTD is poor value based on its PEG Ratio (3.2x)


Price to Book Ratio

PB vs Industry: HTD is overvalued based on its PB Ratio (4.7x) compared to the DE Pharmaceuticals industry average (2.3x).


Next Steps

Future Growth

How is Corcept Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

5.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HTD's forecast earnings growth (5.8% per year) is above the savings rate (-0.4%).

Earnings vs Market: HTD's earnings (5.8% per year) are forecast to grow slower than the German market (13.3% per year).

High Growth Earnings: HTD's earnings are forecast to grow, but not significantly.

Revenue vs Market: HTD's revenue (6.7% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: HTD's revenue (6.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HTD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Corcept Therapeutics performed over the past 5 years?

64.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HTD has high quality earnings.

Growing Profit Margin: HTD's current net profit margins (30.4%) are lower than last year (63.8%).


Past Earnings Growth Analysis

Earnings Trend: HTD has become profitable over the past 5 years, growing earnings by 64% per year.

Accelerating Growth: HTD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HTD had negative earnings growth (-42.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-5%).


Return on Equity

High ROE: HTD's Return on Equity (26%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Corcept Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: HTD's short term assets ($267.3M) exceed its short term liabilities ($32.4M).

Long Term Liabilities: HTD's short term assets ($267.3M) exceed its long term liabilities ($250.0K).


Debt to Equity History and Analysis

Debt Level: HTD is debt free.

Reducing Debt: HTD currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: HTD has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: HTD has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: HTD has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if HTD's debt is covered by short term assets.


Next Steps

Dividend

What is Corcept Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HTD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HTD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HTD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HTD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HTD's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Joseph Belanoff (62yo)

21.1yrs

Tenure

US$6,314,617

Compensation

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h ...


CEO Compensation Analysis

Compensation vs Market: Joseph's total compensation ($USD6.31M) is above average for companies of similar size in the German market ($USD1.51M).

Compensation vs Earnings: Joseph's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Belanoff
Co-Founder21.1yrsUS$6.31m2.2% $32.3m
Gary Robb
CFO & Secretary8.4yrsUS$2.85m0.017% $246.7k
Sean Maduck
Senior Vice President of Commercial3.8yrsUS$2.81m0.044% $641.5k
Christopher James
Director of Investor Relations0yrsno datano data
Hazel Hunt
Senior Vice President of Research2.9yrsno datano data
Donald Laferle
Senior Vice President0yrsno datano data
Andreas Grauer
Chief Medical Officer0.9yrsno datano data

3.8yrs

Average Tenure

57yo

Average Age

Experienced Management: HTD's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joseph Belanoff
Co-Founder21.1yrsUS$6.31m2.2% $32.3m
George Baker
Independent Director21.1yrsUS$267.89k4.43% $65.0m
David Mahoney
Independent Director15.6yrsUS$272.89k1.02% $15.0m
Charles Nemeroff
Member of Scientific Advisory Board0yrsno datano data
James Wilson
Independent Chairman21.1yrsUS$758.67k2.17% $31.8m
Daniel Swisher
Independent Director4.7yrsUS$280.26kno data
Florian Holsboer
Member of Scientific Advisory Board0yrsno datano data
Bruce McEwen
Member of Scientific Advisory Board0yrsno datano data
Ned Kalin
Member of Scientific Advisory Board0yrsno datano data
K. Ranga Krishnan
Member of Scientific Advisory Board0yrsno datano data

21.1yrs

Average Tenure

65yo

Average Age

Experienced Board: HTD's board of directors are seasoned and experienced ( 21.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Corcept Therapeutics Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Corcept Therapeutics Incorporated
  • Ticker: HTD
  • Exchange: DB
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.582b
  • Listing Market Cap: US$1.466b
  • Shares outstanding: 114.28m
  • Website: https://www.corcept.com

Number of Employees


Location

  • Corcept Therapeutics Incorporated
  • 149 Commonwealth Drive
  • Menlo Park
  • California
  • 94025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CORTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2004
HTDDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2004
0I3QLSE (London Stock Exchange)YesCommon StockGBUSDApr 2004

Biography

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing’s syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 20:35
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.